Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
PaperCitations, authors & open-access status
CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 57 citations, 2022 year and closed oa status.
57
Citations
2022
Year
closed
OA Status